Edgewise Therapeutics is developing oral therapeutics targeting serious skeletal and cardiac muscle diseases, including a selective cardiac sarcomere modulator for hypertrophic cardiomyopathy and a fast skeletal myosin inhibitor for muscular dystrophies. The company addresses the unmet medical needs of patients suffering from life-limiting muscle disorders by advancing novel treatment options.
Funding
$240M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Serious skeletal and cardiac muscle diseases, such as muscular dystrophies and hypertrophic cardiomyopathy, have limited effective treatment options, resulting in significant unmet medical needs for affected patients. These life-limiting muscle disorders often lead to impaired muscle function and reduced quality of life.
Solution
Edgewise Therapeutics is developing a portfolio of novel, oral therapeutics designed to address the underlying mechanisms of serious muscle diseases. Their approach involves precision therapeutics targeting key proteins involved in muscle function, including a selective cardiac sarcomere modulator (EDG-7500) for hypertrophic cardiomyopathy and a fast skeletal myosin inhibitor (sevasemten) for muscular dystrophies like Becker and Duchenne. Sevasemten aims to protect dystrophic muscle against contraction-induced injury, while EDG-7500 is designed to slow early contraction velocity and improve cardiac relaxation. These investigational therapies are currently in various stages of clinical development, with the goal of preserving and improving muscle function in patients with life-limiting muscle disorders.
Target Audience
The primary target audience includes patients suffering from serious skeletal and cardiac muscle diseases, such as Becker muscular dystrophy, Duchenne muscular dystrophy, and hypertrophic cardiomyopathy, as well as the physicians and specialists who treat these conditions.
Features
- EDG-7500: Oral, selective cardiac sarcomere modulator specifically designed to slow early contraction velocity and address impaired cardiac relaxation
- Sevasemten: First-in-class, orally-administered fast skeletal myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced injury
- Clinical trials are ongoing for Becker muscular dystrophy, Duchenne muscular dystrophy and hypertrophic cardiomyopathy
- Investigational therapies address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction